Pathophysiological implications of insulin resistance on vascular endothelial function

Background Insulin resistance is a key component of the insulin resistance syndrome and is a crucially important metabolic abnormality in Type 2 diabetes. Insulin‐resistant individuals are at significantly increased risk of cardiovascular disease, although the underlying mechanisms remain incompletely understood. The endothelium is thought to play a critical role in maintaining vascular homeostasis, a process dependent on the balance between the production of nitric oxide, superoxide and other vasoactive substances. Endothelial dysfunction has been demonstrated in insulin‐resistant states in animals and humans and may represent an important early event in the development of atherosclerosis. Insulin resistance may be linked to endothelial dysfunction by a number of mechanisms, including disturbances of subcellular signalling pathways common to both insulin action and nitric oxide production. Other potential unifying links include the roles of oxidant stress, endothelin, the renin angiotensin system and the secretion of hormones and cytokines by adipose tissue. Lifestyle measures and drug therapies which improve insulin sensitivity and ameliorate endothelial dysfunction may be important in delaying the progression to overt cardiovascular disease in at risk individuals.

[1]  M. Shichiri,et al.  Bradykinin enhances GLUT4 translocation through the increase of insulin receptor tyrosine kinase in primary adipocytes: evidence that bradykinin stimulates the insulin signalling pathway , 1996, Diabetologia.

[2]  G. Paolisso,et al.  Oxidative stress and insulin action: is there a relationship? , 1996, Diabetologia.

[3]  H. Yki-Järvinen Insulin resistance and endothelial dysfunction. , 2003, Best practice & research. Clinical endocrinology & metabolism.

[4]  D. Heymann,et al.  Deadly comrades: war and infectious diseases , 2002, The Lancet.

[5]  AndrewJ. S. Coats MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.

[6]  R. Garofalo,et al.  Positive and negative regulatory role of insulin receptor substrate 1 and 2 (IRS-1 and IRS-2) serine/threonine phosphorylation. , 2002, Biochemistry.

[7]  A. Shah,et al.  Acute haemodynamic effects of lipolysis-induced increase of free fatty acids in healthy men. , 2002, Clinical science.

[8]  E. Bonora,et al.  Insulin Causes Endothelial Dysfunction in Humans: Sites and Mechanisms , 2002, Circulation.

[9]  A. Saltiel,et al.  Insulin signaling pathways in time and space. , 2002, Trends in cell biology.

[10]  W. Dietz,et al.  Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. , 2002, JAMA.

[11]  A. Coats MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20 536 high-risk individuals: a randomised placebo-controlled trial , 2002 .

[12]  H. Gavras,et al.  Role of the B2 Receptor of Bradykinin in Insulin Sensitivity , 2001, Hypertension.

[13]  Margaret S. Wu,et al.  Role of AMP-activated protein kinase in mechanism of metformin action. , 2001, The Journal of clinical investigation.

[14]  A. Marette,et al.  Targeted disruption of inducible nitric oxide synthase protects against obesity-linked insulin resistance in muscle , 2001, Nature Medicine.

[15]  Y. Kaneda,et al.  Leptin Induces Mitochondrial Superoxide Production and Monocyte Chemoattractant Protein-1 Expression in Aortic Endothelial Cells by Increasing Fatty Acid Oxidation via Protein Kinase A* , 2001, The Journal of Biological Chemistry.

[16]  D. Webb,et al.  Activation of the endothelin system in insulin resistance. , 2001, QJM : monthly journal of the Association of Physicians.

[17]  D. Weiss,et al.  Angiotensin II and atherosclerosis. , 2001, The American journal of cardiology.

[18]  K. Kamata,et al.  Effect of chronic insulin treatment on NO production and endothelium-dependent relaxation in aortae from established STZ-induced diabetic rats. , 2001, Atherosclerosis.

[19]  K. Mather,et al.  Improved endothelial function with metformin in type 2 diabetes mellitus. , 2001, Journal of the American College of Cardiology.

[20]  R. Schmieder,et al.  Rapid improvement of nitric oxide bioavailability after lipid-lowering therapy with cerivastatin within two weeks. , 2001, Journal of the American College of Cardiology.

[21]  John P H Wilding,et al.  Troglitazone corrects metabolic changes but not vascular dysfunction in dietary-obese rats. , 2001, European journal of pharmacology.

[22]  É. Hajduch,et al.  Protein kinase B (PKB/Akt) – a key regulator of glucose transport? , 2001, FEBS letters.

[23]  Bruce M. Spiegelman,et al.  Obesity and the Regulation of Energy Balance , 2001, Cell.

[24]  A. Saltiel New Perspectives into the Molecular Pathogenesis and Treatment of Type 2 Diabetes , 2001, Cell.

[25]  R. Paschke,et al.  Plasma levels of tumor necrosis factor-alpha, angiotensin II, growth hormone, and IGF-I are not elevated in insulin-resistant obese individuals with impaired glucose tolerance. , 2001, Diabetes care.

[26]  D. Stewart,et al.  Endothelin Antagonism Uncovers Insulin-Mediated Vasorelaxation In Vitro and In Vivo , 2001, Hypertension.

[27]  T. Rabelink,et al.  Cellular regulation of endothelial nitric oxide synthase. , 2001, American journal of physiology. Renal physiology.

[28]  A. M. Lefer,et al.  Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease. , 2001, Cardiovascular research.

[29]  P W Macfarlane,et al.  Pravastatin and the Development of Diabetes Mellitus: Evidence for a Protective Treatment Effect in the West of Scotland Coronary Prevention Study , 2001, Circulation.

[30]  M. Lazar,et al.  The hormone resistin links obesity to diabetes , 2001, Nature.

[31]  J. Mckenney,et al.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.

[32]  C. Kahn,et al.  Unraveling the mechanism of action of thiazolidinediones. , 2000, The Journal of clinical investigation.

[33]  B. Winters,et al.  Reduction of obesity, as induced by leptin, reverses endothelial dysfunction in obese (Lep(ob)) mice. , 2000, Journal of applied physiology.

[34]  D. Harrison,et al.  Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. , 2000, Circulation research.

[35]  T. Lüscher,et al.  Endothelins and Endothelin Receptor Antagonists: Therapeutic Considerations for a Novel Class of Cardiovascular Drugs , 2000, Circulation.

[36]  D. Green,et al.  Losartan, an angiotensin type 1 receptor antagonist, improves endothelial function in non-insulin-dependent diabetes. , 2000, Journal of the American College of Cardiology.

[37]  H. Utsumi,et al.  High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C--dependent activation of NAD(P)H oxidase in cultured vascular cells. , 2000, Diabetes.

[38]  M. Quon,et al.  Insulin action in vascular endothelium: potential mechanisms linking insulin resistance with hypertension , 2000, Diabetes, obesity & metabolism.

[39]  H. Maegawa,et al.  Oral Administration of Tetrahydrobiopterin Prevents Endothelial Dysfunction and Vascular Oxidative Stress in the Aortas of Insulin-Resistant Rats , 2000, Circulation research.

[40]  M. Kanzaki,et al.  CAP defines a second signalling pathway required for insulin-stimulated glucose transport , 2000, Nature.

[41]  D. Hassall,et al.  PPAR agonists as direct modulators of the vessel wall in cardiovascular disease , 2000, Medicinal research reviews.

[42]  L. Lind,et al.  The impairment in endothelial function induced by non-esterified fatty acids can be reversed by insulin. , 2000, Clinical science.

[43]  T. Lüscher Endothelial dysfunction: the role and impact of the renin-angiotensin system , 2000, Heart.

[44]  K. Nakao,et al.  Insulin resistance and endothelial dysfunction in smokers: effects of vitamin C. , 2000, American journal of physiology. Heart and circulatory physiology.

[45]  E. Anggard,et al.  Antioxidants, diabetes and endothelial dysfunction. , 2000, Cardiovascular research.

[46]  J. Olefsky Treatment of insulin resistance with peroxisome proliferator–activated receptor γ agonists , 2000 .

[47]  A. Shah,et al.  Molecular characterization and localization of the NAD(P)H oxidase components gp91-phox and p22-phox in endothelial cells. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[48]  G. Garcı́a-Cardeña,et al.  Reconstitution of an Endothelial Nitric-oxide Synthase (eNOS), hsp90, and Caveolin-1 Complex in Vitro , 2000, The Journal of Biological Chemistry.

[49]  Robert Ross,et al.  Reduction in Obesity and Related Comorbid Conditions after Diet-Induced Weight Loss or Exercise-Induced Weight Loss in Men , 2000, Annals of Internal Medicine.

[50]  I. Nishio,et al.  Involvement of nitric oxide in endothelium-dependent arterial relaxation by leptin. , 2000, Biochemical and biophysical research communications.

[51]  L. Monti,et al.  Relationship between endothelin-1 concentration and metabolic alterations typical of the insulin resistance syndrome. , 2000, Metabolism: clinical and experimental.

[52]  T. Inoue,et al.  Insulin resistance affects endothelium-dependent acetylcholine-induced coronary artery response. , 2000, European heart journal.

[53]  G. Riccardi,et al.  Dietary treatment of the metabolic syndrome — the optimal diet , 2000, British Journal of Nutrition.

[54]  S. Engeli,et al.  Physiology and pathophysiology of the adipose tissue renin-angiotensin system. , 2000, Hypertension.

[55]  K. Channon,et al.  Vascular superoxide production by NAD(P)H oxidase: association with endothelial dysfunction and clinical risk factors. , 2000, Circulation research.

[56]  J. Connell,et al.  Trandolapril does not improve insulin sensitivity in patients with hypertension and type 2 diabetes: a double-blind, placebo-controlled crossover trial. , 2000, The Journal of clinical endocrinology and metabolism.

[57]  J. Connell,et al.  Endothelial dysfunction as a possible link between C-reactive protein levels and cardiovascular disease. , 2000, Clinical science.

[58]  A M Zeiher,et al.  Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. , 2000, Circulation.

[59]  J. W. Meyer,et al.  A central role for the endothelial NADPH oxidase in atherosclerosis , 2000, FEBS letters.

[60]  S. Jacob,et al.  Endothelial dysfunction is detectable in young normotensive first-degree relatives of subjects with type 2 diabetes in association with insulin resistance. , 2000, Circulation.

[61]  M. Quon,et al.  Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells. , 2000, Circulation.

[62]  W. Goettsch,et al.  Endothelin-1 induces NAD(P)H oxidase in human endothelial cells. , 2000, Biochemical and biophysical research communications.

[63]  D. Sorescu,et al.  NAD(P)H oxidase: role in cardiovascular biology and disease. , 2000, Circulation research.

[64]  J. Jukema,et al.  Not acute but chronic hypertriglyceridemia is associated with impaired endothelium-dependent vasodilation: reversal after lipid-lowering therapy by atorvastatin. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[65]  G. King,et al.  Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo : a specific vascular action of insulin. , 2000, Circulation.

[66]  C. Kahn,et al.  Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. , 2000, The Journal of clinical investigation.

[67]  J. Westerbacka,et al.  Insulin therapy improves endothelial function in type 2 diabetes. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[68]  I. Keber,et al.  Physical training improves flow-mediated dilation in patients with the polymetabolic syndrome. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[69]  A. Zeiher,et al.  Insulin-mediated stimulation of protein kinase Akt: A potent survival signaling cascade for endothelial cells. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[70]  M. Laakso,et al.  Insulin resistance syndrome predicts the risk of coronary heart disease and stroke in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[71]  L. Fratta,et al.  Leptin induces direct vasodilation through distinct endothelial mechanisms. , 2000, Diabetes.

[72]  Bruce H. R. Wolffenbuttel,et al.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy , 2000, The Lancet.

[73]  S. Yusuf,et al.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[74]  S. Yusuf,et al.  Vitamin E supplementation and cardiovascular events in high-risk patients. , 2000, The New England journal of medicine.

[75]  A. Saltiel,et al.  Signaling pathways in insulin action: molecular targets of insulin resistance. , 2000, The Journal of clinical investigation.

[76]  M. Katovich,et al.  Effects of inhibition of the renin‐angiotensin system on the cardiovascular actions of insulin , 2000, Diabetes, obesity & metabolism.

[77]  M. Hecker,et al.  Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[78]  J. Olefsky Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists. , 2000, The Journal of clinical investigation.

[79]  J. Connell,et al.  Insulin action is associated with endothelial function in hypertension and type 2 diabetes. , 2000, Hypertension.

[80]  M. Hoenig,et al.  Metformin improves vascular function in insulin-resistant rats. , 2000, Hypertension.

[81]  C. Kahn,et al.  Crosstalk between insulin and angiotensin II signalling systems. , 2009, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[82]  A. Kashiwagi,et al.  Abnormal biopterin metabolism is a major cause of impaired endothelium-dependent relaxation through nitric oxide/O2- imbalance in insulin-resistant rat aorta. , 1999, Diabetes.

[83]  H. Maegawa,et al.  Endothelium-specific activation of NAD(P)H oxidase in aortas of exogenously hyperinsulinemic rats. , 1999, American journal of physiology. Endocrinology and metabolism.

[84]  R. Bergman,et al.  Angiotensin II induces insulin resistance independent of changes in interstitial insulin. , 1999, The American journal of physiology.

[85]  P. Zimmet,et al.  Etiology of the Metabolic Syndrome: Potential Role of Insulin Resistance, Leptin Resistance, and Other Players , 1999, Annals of the New York Academy of Sciences.

[86]  P. Strålfors,et al.  Localization of the insulin receptor in caveolae of adipocyte plasma membrane , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[87]  Y. Yazaki,et al.  Imidapril, an angiotensin-converting enzyme inhibitor, improves insulin sensitivity by enhancing signal transduction via insulin receptor substrate proteins and improving vascular resistance in the Zucker fatty rat. , 1999, Metabolism: clinical and experimental.

[88]  A. Kashiwagi,et al.  Free radical production in endothelial cells as a pathogenetic factor for vascular dysfunction in the insulin resistance state. , 1999, Diabetes research and clinical practice.

[89]  D. M. Rocha,et al.  Overnight lowering of free fatty acids with Acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects. , 1999, Diabetes.

[90]  M. Carrier,et al.  Pro‐oxidant challenge in vivo provokes the onset of NIDDM in the insulin resistant obese Zucker rat , 1999, British journal of pharmacology.

[91]  Y. Ikeda,et al.  Insulin Signaling Is Inhibited by Micromolar Concentrations of H2O2 , 1999, The Journal of Biological Chemistry.

[92]  R. Busse,et al.  Signal transduction of eNOS activation. , 1999, Cardiovascular research.

[93]  M. White,et al.  Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa) rats. , 1999, The Journal of clinical investigation.

[94]  B. Mayer,et al.  Enzymatic function of nitric oxide synthases. , 1999, Cardiovascular research.

[95]  R. D. Rudic,et al.  Molecular control of nitric oxide synthases in the cardiovascular system. , 1999, Cardiovascular research.

[96]  A. Hofman,et al.  Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[97]  B. Kahn,et al.  Glucose transporters and insulin action--implications for insulin resistance and diabetes mellitus. , 1999, The New England journal of medicine.

[98]  S. Jacob,et al.  ACE inhibition and glucose transport in insulinresistant muscle: roles of bradykinin and nitric oxide. , 1999, The American journal of physiology.

[99]  G. Williams,et al.  The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats. , 1999, Diabetes.

[100]  N. Schneiderman,et al.  Is fasting leptin associated with insulin resistance among nondiabetic individuals? The Miami Community Health Study. , 1999, Diabetes care.

[101]  S. Jacob,et al.  ACE inhibition and glucose transport in insulinresistant muscle: roles of bradykinin and nitric oxide. , 1999, American journal of physiology. Regulatory, integrative and comparative physiology.

[102]  R. Busse,et al.  Leptin induces oxidative stress in human endothelial cells , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[103]  K. Williams,et al.  Atherosclerosis--an inflammatory disease. , 1999, The New England journal of medicine.

[104]  R. Busse,et al.  Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation , 1999, Nature.

[105]  G. Hotamisligil The role of TNFα and TNF receptors in obesity and insulin resistance , 1999 .

[106]  M. Laakso,et al.  Hyperglycemia and cardiovascular disease in type 2 diabetes. , 1999, Diabetes.

[107]  D. Green,et al.  Improvement in endothelial function by angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. , 1999, Journal of the American College of Cardiology.

[108]  M. White,et al.  Endothelin-1 modulates insulin signaling through phosphatidylinositol 3-kinase pathway in vascular smooth muscle cells. , 1999, Diabetes.

[109]  C. Juan,et al.  Exogenous hyperinsulinemia causes insulin resistance, hyperendothelinemia, and subsequent hypertension in rats. , 1999, Metabolism: clinical and experimental.

[110]  C. Kahn,et al.  Protein-protein interaction in insulin signaling and the molecular mechanisms of insulin resistance. , 1999, The Journal of clinical investigation.

[111]  S. Coppack,et al.  C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[112]  R. Rosenson,et al.  Inhibition of proinflammatory cytokine production by pravastatin , 1999, The Lancet.

[113]  R. Andrade,et al.  Fulminant liver failure associated with flutamide therapy for hirsutism , 1999, The Lancet.

[114]  G. Winkler,et al.  Elevated serum TNF‐α level as a link between endothelial dysfunction and insulin resistance in normotensive obese patients , 1999, Diabetic medicine : a journal of the British Diabetic Association.

[115]  R. Busse,et al.  Vascular endothelial growth factor up-regulates nitric oxide synthase expression in endothelial cells. , 1999, Cardiovascular research.

[116]  J. Pessin,et al.  Molecular Basis of Insulin-stimulated GLUT4 Vesicle Trafficking , 1999, The Journal of Biological Chemistry.

[117]  M. Czech,et al.  Signaling Mechanisms That Regulate Glucose Transport* , 1999, The Journal of Biological Chemistry.

[118]  A. Döring,et al.  C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. , 1999, Circulation.

[119]  D L Rothman,et al.  Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. , 1999, The Journal of clinical investigation.

[120]  G. Hotamisligil The role of TNFalpha and TNF receptors in obesity and insulin resistance. , 1999, Journal of internal medicine.

[121]  Y. Ikeda,et al.  Insulin signaling is inhibited by micromolar concentrations of H(2)O(2). Evidence for a role of H(2)O(2) in tumor necrosis factor alpha-mediated insulin resistance. , 1999, The Journal of biological chemistry.

[122]  R. Caldwell,et al.  Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. , 1999, Journal of the American College of Cardiology.

[123]  A. Sidawy,et al.  Insulin action enhancement normalizes brachial artery vasoactivity in patients with peripheral vascular disease and occult diabetes. , 1998, Journal of vascular surgery.

[124]  K. Ichihara,et al.  Fluvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl-CoA reductase, scavenges free radicals and inhibits lipid peroxidation in rat liver microsomes. , 1998, European journal of pharmacology.

[125]  S. Hunter,et al.  Captopril does not improve insulin action in essential hypertension: A double‐blind placebo‐controlled study , 1998, Journal of hypertension.

[126]  S. Chatterjee Sphingolipids in atherosclerosis and vascular biology. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[127]  M. Carrier,et al.  Investigation of oxidant stress and vasodepression to glyceryl trinitrate in the obese Zucker rat in vivo , 1998, British journal of pharmacology.

[128]  A. Rudich,et al.  Prolonged oxidative stress impairs insulin-induced GLUT4 translocation in 3T3-L1 adipocytes. , 1998, Diabetes.

[129]  R. Fogari,et al.  ACE inhibition but not angiotensin II antagonism reduces plasma fibrinogen and insulin resistance in overweight hypertensive patients. , 1998, Journal of cardiovascular pharmacology.

[130]  Philip D. Harvey,et al.  Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39 , 1998, BMJ.

[131]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[132]  G. Garcı́a-Cardeña,et al.  Biological action of leptin as an angiogenic factor. , 1998, Science.

[133]  R. Holman,et al.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) , 1998, The Lancet.

[134]  M. Hoenig,et al.  Endothelial dysfunction precedes hypertension in diet-induced insulin resistance. , 1998, American journal of physiology. Regulatory, integrative and comparative physiology.

[135]  Uk-Prospective-Diabetes-Study-Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) , 1998, The Lancet.

[136]  T. Wadden,et al.  Tumor Necrosis Factor-α in Sera of Obese Patients: Fall with Weight Loss , 1998 .

[137]  D. Hayoz,et al.  Nitric oxide synthase expression in endothelial cells exposed to mechanical forces. , 1998, Hypertension.

[138]  W A Hsueh,et al.  Cardiovascular risk continuum: implications of insulin resistance and diabetes. , 1998, The American journal of medicine.

[139]  H. Lithell,et al.  Insulin resistance in essential hypertension is related to plasma renin activity , 1998, Journal of Human Hypertension.

[140]  M. Makuuchi,et al.  Hypertension, hypertriglyceridemia, and impaired endothelium-dependent vascular relaxation in mice lacking insulin receptor substrate-1. , 1998, The Journal of clinical investigation.

[141]  C. Tack,et al.  Insulin-induced vasodilatation and endothelial function in obesity/insulin resistance. Effects of troglitazone , 1998, Diabetologia.

[142]  U. Laufs,et al.  Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. , 1998, Circulation.

[143]  H. Yki-Järvinen,et al.  Insulin-induced vasodilatation: physiology or pharmacology? , 1998, Diabetologia.

[144]  J. Knuuti,et al.  Insulin resistance of glucose uptake in skeletal muscle cannot be ameliorated by enhancing endothelium-dependent blood flow in obesity. , 1998, The Journal of clinical investigation.

[145]  T. Michel,et al.  The Endothelial Nitric-oxide Synthase-Caveolin Regulatory Cycle* , 1998, The Journal of Biological Chemistry.

[146]  G. D. De Keulenaer,et al.  Tumour necrosis factor alpha activates a p22phox-based NADH oxidase in vascular smooth muscle. , 1998, The Biochemical journal.

[147]  T. Lüscher,et al.  Atherosclerosis and the two faces of endothelial nitric oxide synthase. , 1998, Circulation.

[148]  L. Goodyear,et al.  Exercise, glucose transport, and insulin sensitivity. , 1998, Annual review of medicine.

[149]  P. Vanhoutte Endothelial dysfunction and vascular disease. , 1998, Verhandelingen - Koninklijke Academie voor Geneeskunde van Belgie.

[150]  I. Macdonald,et al.  Depressor action of insulin on skeletal muscle vasculature: a novel mechanism for postprandial hypotension in the elderly. , 1998, Journal of the American College of Cardiology.

[151]  T. Wadden,et al.  Tumor necrosis factor-alpha in sera of obese patients: fall with weight loss. , 1998, The Journal of clinical endocrinology and metabolism.

[152]  E. Block,et al.  A Caveolar Complex between the Cationic Amino Acid Transporter 1 and Endothelial Nitric-oxide Synthase May Explain the “Arginine Paradox”* , 1997, The Journal of Biological Chemistry.

[153]  J S Yudkin,et al.  Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1997 by The Endocrine Society Subcutaneous Adipose Tissue Releases Interleukin-6, But Not Tumor Necrosis Factor-�, in Vivo* , 2022 .

[154]  K. Schenck-Gustafsson,et al.  Transient triglyceridemia decreases vascular reactivity in young, healthy men without risk factors for coronary heart disease. , 1997, Circulation.

[155]  P. Vallance,et al.  Inflammatory cytokines impair endothelium-dependent dilatation in human veins in vivo. , 1997, Circulation.

[156]  O. Feron,et al.  Nitric oxide synthases: which, where, how, and why? , 1997, Journal of Clinical Investigation.

[157]  D. Harrison,et al.  Cellular and molecular mechanisms of endothelial cell dysfunction. , 1997, The Journal of clinical investigation.

[158]  K. Uysal,et al.  Protection from obesity-induced insulin resistance in mice lacking TNF-α function , 1997, Nature.

[159]  E. Kraegen,et al.  PATHOGENESIS OF THE INSULIN RESISTANCE SYNDROME (SYNDROME X) , 1997, Clinical and experimental pharmacology & physiology.

[160]  S. Coppack,et al.  Endothelial Dysfunction: Cause of the Insulin Resistance Syndrome , 1997, Diabetes.

[161]  G. Ahlborg,et al.  Exogenous endothelin-1 causes peripheral insulin resistance in healthy humans. , 1997, Acta physiologica Scandinavica.

[162]  I. Laher,et al.  Reactivity of mesenteric arteries from fructose hypertensive rats to endothelin-1. , 1997, American journal of hypertension.

[163]  A. Mark,et al.  Sympathetic and cardiorenal actions of leptin. , 1997, Hypertension.

[164]  A. Baron,et al.  Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation. , 1997, The Journal of clinical investigation.

[165]  H. Ju,et al.  Direct Interaction of Endothelial Nitric-oxide Synthase and Caveolin-1 Inhibits Synthase Activity* , 1997, The Journal of Biological Chemistry.

[166]  A. Marette,et al.  Cytokines modulate glucose transport in skeletal muscle by inducing the expression of inducible nitric oxide synthase. , 1997, The Biochemical journal.

[167]  L. M. Leeb-Lundberg,et al.  Bradykinin Sequesters B2 Bradykinin Receptors and the Receptor-coupled Gα Subunits Gαq and Gαiin Caveolae in DDT1 MF-2 Smooth Muscle Cells* , 1997, The Journal of Biological Chemistry.

[168]  K. Alberti,et al.  The changing face of macrovascular disease in non-insulin-dependent diabetes mellitus: an epidemic in progress , 1997, The Lancet.

[169]  S. O’Rahilly,et al.  Congenital leptin deficiency is associated with severe early-onset obesity in humans , 1997, Nature.

[170]  D. Sacks,et al.  Reciprocal Regulation of Endothelial Nitric-oxide Synthase by Ca2+-Calmodulin and Caveolin* , 1997, The Journal of Biological Chemistry.

[171]  J. Zierath,et al.  Insulin Receptor Substrate-1 Phosphorylation and Phosphatidylinositol 3-Kinase Activity in Skeletal Muscle From NIDDM Subjects After In Vivo Insulin Stimulation , 1997, Diabetes.

[172]  G. Boden Role of Fatty Acids in the Pathogenesis of Insulin Resistance and NIDDM , 1997, Diabetes.

[173]  K. Uysal,et al.  Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. , 1997, Nature.

[174]  C. Juan,et al.  Endothelin-1 induces insulin resistance in conscious rats. , 1996, Biochemical and biophysical research communications.

[175]  I. Macdonald,et al.  Effect of a physiological insulin infusion on the cardiovascular responses to a high fat meal: evidence supporting a role for insulin in modulating postprandial cardiovascular homoeostasis in man. , 1996, Clinical science.

[176]  M. Quon,et al.  Insulin-stimulated production of nitric oxide is inhibited by wortmannin. Direct measurement in vascular endothelial cells. , 1996, The Journal of clinical investigation.

[177]  M. Brown,et al.  A Randomised Controlled Trial of Vitamin E in Patients with Coronary Disease: The Cambridge Heart Antioxidant Study (CHAOS) , 1996 .

[178]  G. Garcı́a-Cardeña,et al.  Targeting of nitric oxide synthase to endothelial cell caveolae via palmitoylation: implications for nitric oxide signaling. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[179]  S. Snyder,et al.  Nitric oxide synthase generates superoxide and nitric oxide in arginine-depleted cells leading to peroxynitrite-mediated cellular injury. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[180]  K. Petersen,et al.  Mechanism of free fatty acid-induced insulin resistance in humans. , 1996, The Journal of clinical investigation.

[181]  A. Baron,et al.  Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. , 1996, The Journal of clinical investigation.

[182]  D. Harrison,et al.  Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. , 1996, The Journal of clinical investigation.

[183]  G. Dagenais,et al.  Hyperinsulinemia as an independent risk factor for ischemic heart disease. , 1996, The New England journal of medicine.

[184]  D. Webb,et al.  Endothelial nitric oxide production and insulin sensitivity. A physiological link with implications for pathogenesis of cardiovascular disease. , 1996, Circulation.

[185]  Richard G. W. Anderson,et al.  Acylation Targets Endothelial Nitric-oxide Synthase to Plasmalemmal Caveolae (*) , 1996, The Journal of Biological Chemistry.

[186]  C. Ferri,et al.  Circulating catecholamines and metabolic effects of captopril in NIDDM patients , 1996, Diabetes Care.

[187]  L. Tartaglia,et al.  Phenotypes of Mouse diabetes and Rat fatty Due to Mutations in the OB (Leptin) Receptor , 1996, Science.

[188]  R. Henry,et al.  The expression of TNF alpha by human muscle. Relationship to insulin resistance. , 1996, The Journal of clinical investigation.

[189]  T. Lüscher,et al.  Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. , 1996, Circulation.

[190]  R. Considine,et al.  Serum immunoreactive-leptin concentrations in normal-weight and obese humans. , 1996, The New England journal of medicine.

[191]  S. Jacob,et al.  Potential Role of Bradykinin in Forearm Muscle Metabolism in Humans , 1996, Diabetes.

[192]  Farris K. Timimi,et al.  Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus. , 1996, The Journal of clinical investigation.

[193]  T. Michel,et al.  Mutagenesis of palmitoylation sites in endothelial nitric oxide synthase identifies a novel motif for dual acylation and subcellular targeting. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[194]  S. Bhanot,et al.  Effect of chronic endothelin blockade in hyperinsulinemic hypertensive rats. , 1995, The American journal of physiology.

[195]  J. Olefsky,et al.  Insulin-stimulated GLUT4 Translocation Is Mediated by a Divergent Intracellular Signaling Pathway (*) , 1995, The Journal of Biological Chemistry.

[196]  P. Lefebvre,et al.  Short Administration of Metformin Improves Insulin Sensitivity in Android Obese Subjects with Impaired Glucose Tolerance , 1995, Diabetic medicine : a journal of the British Diabetic Association.

[197]  B. Egan,et al.  Oleic acid inhibits endothelial nitric oxide synthase by a protein kinase C-independent mechanism. , 1995, Hypertension.

[198]  W. Sessa,et al.  Cyclic strain upregulates nitric oxide synthase in cultured bovine aortic endothelial cells. , 1995, The Journal of clinical investigation.

[199]  Steven L. Cohen,et al.  Weight-reducing effects of the plasma protein encoded by the obese gene. , 1995, Science.

[200]  K. Wu,et al.  Transcriptional Induction of Endothelial Nitric Oxide Synthase Type III by Lysophosphatidylcholine (*) , 1995, The Journal of Biological Chemistry.

[201]  K. Hirata,et al.  Low concentration of oxidized low-density lipoprotein and lysophosphatidylcholine upregulate constitutive nitric oxide synthase mRNA expression in bovine aortic endothelial cells. , 1995, Circulation research.

[202]  F. Giorgino,et al.  Insulin receptor phosphorylation, insulin receptor substrate-1 phosphorylation, and phosphatidylinositol 3-kinase activity are decreased in intact skeletal muscle strips from obese subjects. , 1995, The Journal of clinical investigation.

[203]  B. Spiegelman,et al.  Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. , 1995, The Journal of clinical investigation.

[204]  W. Weintraub,et al.  Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. , 1995, The New England journal of medicine.

[205]  J. Liao,et al.  Oxidized Low-density Lipoprotein Decreases the Expression of Endothelial Nitric Oxide Synthase (*) , 1995, The Journal of Biological Chemistry.

[206]  A. Takeshita,et al.  Role of Nitric Oxide in Exercise‐Induced Vasodilation of the Forearm , 1994, Circulation.

[207]  S. Kostyk,et al.  Hypoxia inhibits expression of eNOS via transcriptional and posttranscriptional mechanisms. , 1994, The American journal of physiology.

[208]  G. Paolisso,et al.  Evidence for a relationship between oxidative stress and insulin action in non-insulin-dependent (type II) diabetic patients. , 1994, Metabolism: clinical and experimental.

[209]  W. Erl,et al.  Antioxidants inhibit monocyte adhesion by suppressing nuclear factor-kappa B mobilization and induction of vascular cell adhesion molecule-1 in endothelial cells stimulated to generate radicals. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[210]  C. Juan,et al.  Endothelin-1 inhibits insulin-stimulated glucose uptake in isolated rat adipocytes. , 1994, Biochemical and biophysical research communications.

[211]  P. Kaminski,et al.  NADH oxidoreductase is a major source of superoxide anion in bovine coronary artery endothelium. , 1994, The American journal of physiology.

[212]  Z. Ba,et al.  Administration of tumor necrosis factor-alpha in vivo depresses endothelium-dependent relaxation. , 1994, The American journal of physiology.

[213]  T. Lüscher The endothelium and cardiovascular disease--a complex relation. , 1994, The New England journal of medicine.

[214]  W. A. Bradley,et al.  Superoxide and peroxynitrite in atherosclerosis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[215]  K. Pritchard,et al.  Chronic exercise in dogs increases coronary vascular nitric oxide production and endothelial cell nitric oxide synthase gene expression. , 1994, Circulation research.

[216]  Brad A. Myers,et al.  Challenges of HCI design and implementation , 1994, INTR.

[217]  H. Adams,et al.  EFFECTS OF CYTOKINES TUMOR NECROSIS FACTOR α AND INTERLEUKIN 1β ON ENDOTOXIN‐MEDIATED INHIBITION OF ENDOTHELIUM‐DERIVED RELAXING FACTOR BIOACTIVITY AND NITRIC OXIDE PRODUCTION IN VASCULAR ENDOTHELIUM , 1994, Shock.

[218]  E. Forsberg,et al.  Effects of ATP and bradykinin on endothelial cell Ca2+ homeostasis and formation of cGMP and prostacyclin. , 1993, The American journal of physiology.

[219]  A. Morris,et al.  Effects of angiotensin II on insulin sensitivity: a placebo-controlled study. , 1993, Clinical science.

[220]  Y. Ebina,et al.  Insulin-stimulated GLUT4 translocation is relevant to the phosphorylation of IRS-1 and the activity of PI3-kinase. , 1993, Biochemical and biophysical research communications.

[221]  D. Fliser,et al.  Angiotensin II enhances insulin sensitivity in healthy volunteers under euglycemic conditions , 1993, Journal of hypertension.

[222]  M. Yoshizumi,et al.  Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life. , 1993, Circulation research.

[223]  E. Rimm,et al.  Vitamin E consumption and the risk of coronary heart disease in men. , 1993, The New England journal of medicine.

[224]  T. Fujimoto Calcium pump of the plasma membrane is localized in caveolae , 1993, Journal of Cell Biology.

[225]  T. Lincoln,et al.  Intracellular cyclic GMP receptor proteins , 1993, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[226]  E. Levin,et al.  Insulin Stimulates Production and Secretion of Endothelin From Bovine Endothelial Cells , 1993, Diabetes.

[227]  R M Nerem,et al.  Molecular cloning and characterization of the constitutive bovine aortic endothelial cell nitric oxide synthase. , 1992, The Journal of clinical investigation.

[228]  A. Lerman,et al.  Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. , 1991, The New England journal of medicine.

[229]  C. Kahn,et al.  Structure of the insulin receptor substrate IRS-1 defines a unique signal transduction protein , 1991, Nature.

[230]  J. Vane,et al.  Diphenylene iodonium, an inhibitor of free radical formation, inhibits platelet aggregation. , 1991, European journal of pharmacology.

[231]  H. Yki-Järvinen,et al.  Effect of free fatty acids on glucose uptake and nonoxidative glycolysis across human forearm tissues in the basal state and during insulin stimulation. , 1991, The Journal of clinical endocrinology and metabolism.

[232]  T. van der Poll,et al.  Tumor necrosis factor mimics the metabolic response to acute infection in healthy humans. , 1991, The American journal of physiology.

[233]  S. Haffner,et al.  Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? , 1990, JAMA.

[234]  G. Reaven Role of Insulin Resistance in Human Disease , 1988, Diabetes.

[235]  G. Reaven Banting lecture 1988. Role of insulin resistance in human disease. , 1988, Diabetes.

[236]  Sadao Kimura,et al.  A novel potent vasoconstrictor peptide produced by vascular endothelial cells , 1988, Nature.

[237]  O. H. Viveros,et al.  Hormonal regulation of guanosine triphosphate cyclohydrolase activity and biopterin levels in the rat adrenal cortex. , 1983, Endocrinology.

[238]  C. Kahn,et al.  Insulin stimulates tyrosine phosphorylation of the insulin receptor in a cell-free system , 1982, Nature.

[239]  L. Hayes,et al.  Angiotensin converting enzyme in cultured endothelial cells and growth medium. Relationships to enzyme from kidney and plasma. , 1981, Biochimica et biophysica acta.

[240]  F. Murad,et al.  Nitric oxide activates guanylate cyclase and increases guanosine 3':5'-cyclic monophosphate levels in various tissue preparations. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[241]  A. Montagu NATURAL SELECTION AND MAN'S RELATIVE HAIRLESSNESS. , 1964, JAMA.